Cargando…

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy

SIMPLE SUMMARY: Innovative strategies to reduce immune suppression and activate tumor-specific immunity are needed to help patients who do not respond or become resistant to immune checkpoint blockade therapies. In this study, we demonstrate that the addition of a cancer vaccine targeting a tumor-as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horn, Lucas A., Fousek, Kristen, Hamilton, Duane H., Hodge, James W., Zebala, John A., Maeda, Dean Y., Schlom, Jeffrey, Palena, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956439/ https://www.ncbi.nlm.nih.gov/pubmed/33669155 http://dx.doi.org/10.3390/cancers13050968

Ejemplares similares

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
por: Fousek, Kristen, et al.
Publicado: (2023)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
por: Hamilton, Duane H., et al.
Publicado: (2014)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
por: Horn, Lucas A., et al.
Publicado: (2022)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
por: Hamilton, Duane H., et al.
Publicado: (2013)

Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses
por: Palena, Claudia, et al.
Publicado: (2010)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
por: Palena, Claudia, et al.
Publicado: (2014)

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition
por: David, Justin M., et al.
Publicado: (2016)

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
por: David, Justin M., et al.
Publicado: (2017)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy
por: Brito-Orama, Sebastian, et al.
Publicado: (2023)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Characterization of intratumor microbiome in cancer immunotherapy
por: Zhang, Zhao, et al.
Publicado: (2023)

Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas
por: Fernando, Romaine I, et al.
Publicado: (2013)

The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
por: David, Justin M., et al.
Publicado: (2016)

Combination therapies utilizing neoepitope-targeted vaccines
por: Lee, Karin L., et al.
Publicado: (2020)

Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies
por: Nahar, Saifun, et al.
Publicado: (2023)

Repurposing infectious disease vaccines for intratumoral immunotherapy
por: Melero, Ignacio, et al.
Publicado: (2020)

Repurposing the yellow fever vaccine for intratumoral immunotherapy
por: Aznar, Maria Angela, et al.
Publicado: (2019)

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
por: Fernando, Romaine I., et al.
Publicado: (2016)

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment
por: Maldonado, Maria del Mar, et al.
Publicado: (2023)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Intratumoral cancer immunotherapy exploiting anti-viral immunity
por: Kadowaki, Norimitsu
Publicado: (2021)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

Maximizing response to intratumoral immunotherapy in mice by tuning local retention
por: Momin, Noor, et al.
Publicado: (2022)

High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack
por: Hamilton, Duane H, et al.
Publicado: (2013)

Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy
por: Gao, Ran, et al.
Publicado: (2022)

Immunotherapy of primary methylcholanthrene-induced mouse tumours by intratumoral BCG.
por: Creau-Goldberg, N., et al.
Publicado: (1980)

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy
por: Raj, Shailaja, et al.
Publicado: (2018)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hv8simaeet5o65a61t3sd9pvs6